BSE: 524476 | NSE: ZILONPHARM | Pharmaceuticals & Drugs |
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
No data to display
Return on Equity has declined versus last 3 years average to %
|TTM EPS (₹)||-||-|
|TTM Sales (₹ Cr.)||-||-|
|BVPS (₹.) ⓘ||-||-|
|Reserves (₹ Cr.) ⓘ||-||-|
|From the Market|
|52 Week Low / High (₹)||0.00 / 0.00|
|All Time Low / High (₹)||0.50 / 140.00|
|Market Cap (₹ Cr.)||-|
|Equity (₹ Cr.)||-|
|Face Value (₹)||-|
|Industry PE ⓘ||-|
Zillion Pharmachem was incorporated on Aprril 24, 1992. It was promoted by Amit Shah, Bina Shah and Prafulchandra Barot. ZPL manufactures bulk drugs such as antendol, nifedipine, chloro pheniramine, trimethoprim, propanolol HCl and formulations such as ointments, injectables, syrups, capsules, tablets. It markets products under the brand names Zillion and Zee.
It entered into collaboration with Cuba Pharma Havana, Cuba, for products like Hepatitis B Surface Antigen vaccine, Streptokines, Facdermin cream, Meningocolol vaccine B & C, AIDS testing kits, and monoclonal antibiotics. ZPL has export orders worth Rs. 8.5 cr on hand. Export orders amounting to full capacity utilisation have been received from Dubai, Saudi Arabia, Indonesia, Singapore, Thailand, etc
The scrip of the company is suspended for trading since November 30, 2007.